Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
Special Offer: Just $199
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
NASDAQ:MNOV

MediciNova - MNOV Stock Forecast, Price & News

$2.29
+0.10 (+4.57%)
(As of 11/25/2022 04:00 PM ET)
Add
Compare
Today's Range
$2.21
▼
$2.37
50-Day Range
$1.99
▼
$2.29
52-Week Range
$1.96
▼
$3.59
Volume
48,270 shs
Average Volume
47,124 shs
Market Capitalization
$112.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

MediciNova MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
162.0% Upside
$6.00 Price Target
Short Interest
Bearish
1.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.17mentions of MediciNova in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$674 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.20) to ($0.37) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

909th out of 1,044 stocks

Pharmaceutical Preparations Industry

440th out of 510 stocks

See Top Rated MarketRank™ Stocks Here
MNOV stock logo

About MediciNova (NASDAQ:MNOV) Stock

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Stock News Headlines

November 18, 2022 | finance.yahoo.com
MNOV: Well Financed to Get Through Tough Market Conditions…
October 13, 2022 | finance.yahoo.com
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
October 6, 2022 | reuters.com
MNOV.A - MediciNova, Inc. | Stock Price & Latest News | Reuters
September 29, 2022 | americanbankingnews.com
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com
September 16, 2022 | seekingalpha.com
MediciNova to get US patent for MN-166 to treat brain cancer - Seeking Alpha
September 15, 2022 | globenewswire.com
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference - GlobeNewswire
September 15, 2022 | finance.yahoo.com
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference
September 15, 2022 | globenewswire.com
MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma - GlobeNewswire
September 14, 2022 | nasdaq.com
Health Care Sector Update for 09/14/2022: MNOV, PNT, MRNA, XLV, IBB - Nasdaq
September 14, 2022 | finance.yahoo.com
MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
September 14, 2022 | seekingalpha.com
MediciNova to get patent in Canada for MN-001/MN-002 covering certain metabolic disorders
September 14, 2022 | finance.yahoo.com
MediciNova Poised To Receive Canadian Patents For Cholesterol Candidates
September 14, 2022 | finance.yahoo.com
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada - Yahoo Finance
September 13, 2022 | globenewswire.com
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada - GlobeNewswire
September 13, 2022 | finance.yahoo.com
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada
August 24, 2022 | bizjournals.com
Braustin Homes appoints new executives amid a boom in business - San Antonio Business Journal - The Business Journals
August 23, 2022 | finance.yahoo.com
Global Recurrent Glioblastoma Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight - Yahoo Finance
August 19, 2022 | benzinga.com
Phase 2 Trial of MN-001 in Patients with NAFLD, Type 2 Diabetes, and Hypertriglyceridemia Underway
August 16, 2022 | seekingalpha.com
MediciNova's MN-166 to be part of study to treat Long COVID - Seeking Alpha
August 16, 2022 | globenewswire.com
MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID - GlobeNewswire
August 16, 2022 | finance.yahoo.com
MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID
August 9, 2022 | globenewswire.com
MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation - GlobeNewswire
August 9, 2022 | finance.yahoo.com
MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
July 27, 2022 | globenewswire.com
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea - GlobeNewswire
July 27, 2022 | finance.yahoo.com
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea
See More Headlines
Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Company Calendar

Last Earnings
10/26/2020
Today
11/26/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/09/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MNOV
CUSIP
N/A
CIK
1226616
Web
medicinova.com
Phone
(858) 373-1500
Fax
858-404-0048
Employees
11
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+162.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,130,000.00
Net Margins
N/A
Pretax Margin
-2,628,577.25%
Return on Equity
-16.76%
Return on Assets
-15.88%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.74
Quick Ratio
11.74

Sales & Book Value

Annual Sales
$4.04 million
Price / Sales
27.80
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.49 per share
Price / Book
1.54

Miscellaneous

Outstanding Shares
49,050,000
Free Float
40,855,000
Market Cap
$112.32 million
Optionable
Optionable
Beta
0.82

Social Links


Key Executives

  • Dr. Yuichi Iwaki M.D. (Age 72)
    Ph.D., Co-Founder, Pres, CEO & Exec. Director
    Comp: $777.7k
  • Dr. Kazuko Matsuda M.D. (Age 56)
    M.P.H., MPH, Ph.D., Chief Medical Officer & Director
    Comp: $564.13k
  • Mr. Jason J. Kruger CPA (Age 45)
    CFO & Principal Financial Officer
  • Dr. David H. Crean M.B.A. (Age 57)
    Ph.D., Chief Bus. Officer
  • Mr. John O'Neil CPA
    Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MNOV Stock - Frequently Asked Questions

Should I buy or sell MediciNova stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MNOV shares.
View MNOV analyst ratings or view top-rated stocks.

What is MediciNova's stock price forecast for 2023?

1 Wall Street research analysts have issued 12-month price objectives for MediciNova's stock. Their MNOV share price forecasts range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 162.0% from the stock's current price.
View analysts price targets for MNOV or view top-rated stocks among Wall Street analysts.

How have MNOV shares performed in 2022?

MediciNova's stock was trading at $2.68 at the beginning of 2022. Since then, MNOV shares have decreased by 14.6% and is now trading at $2.29.
View the best growth stocks for 2022 here.

When is MediciNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our MNOV earnings forecast.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings results on Monday, October, 26th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.04.

What other stocks do shareholders of MediciNova own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY).

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

Who are MediciNova's major shareholders?

MediciNova's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.45%), Barclays PLC (0.32%), Renaissance Technologies LLC (0.31%), Citadel Advisors LLC (0.05%) and Price T Rowe Associates Inc. MD (0.04%). Insiders that own company stock include Hideki Nagao, Kazuko Matsuda and Yuichi Iwaki.
View institutional ownership trends.

How do I buy shares of MediciNova?

Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $2.29.

How much money does MediciNova make?

MediciNova (NASDAQ:MNOV) has a market capitalization of $112.32 million and generates $4.04 million in revenue each year.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The official website for the company is medicinova.com. The biopharmaceutical company can be reached via phone at (858) 373-1500, via email at info@medicinova.com, or via fax at 858-404-0048.

This page (NASDAQ:MNOV) was last updated on 11/27/2022 by MarketBeat.com Staff